Industry News
Biotechnology Industry News
Amgen has terminated its…
Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.
The ink was barely dry on…
The ink was barely dry on AstraZeneca’s announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion to one of its regional partners.
Moderna has out-licensed a rare…
Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.
Cardiff is churning its leadership…
Cardiff is churning its leadership team as the biotech advances its colorectal cancer candidate onvansertib toward late-stage clinical development. CEO Mark Erlander, Ph.D., and Chief Financial Officer James Levine are both stepping down from their
Henlius CEO Jason Zhu shares how…
Henlius CEO Jason Zhu shares how the biotech balances biosimilars, innovation and global scale.
AI-fueled Formation Bio has inked…
AI-fueled Formation Bio has inked another licensing deal for a China asset, this time picking up an oral small molecule designed to treat autoimmune disease in a deal worth up to $500 million biobucks.
Two and a half years after Sanofi…
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
Roche has waved goodbye to an…
Roche has waved goodbye to an inflammation drug from Kiniksa—as well as the $100 million the pharma paid for the therapy.
AstraZeneca has outlined plans to…
AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.
Sanofi is tight-lipped about the…
Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared to be the final RIPK1 inhibitor from the deal.
With three Big Pharma…
With three Big Pharma collaborations already under its belt, Flagship Pioneering spinout Repertoire Immune Medicines has picked up one more—and its biggest yet—in a further validation of the company’s immune system decoding platform.
After announcing plans to go…
After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million.
As biopharma M&A activity…
As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and
A brain tumor has prompted the FDA…
A brain tumor has prompted the FDA to put clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision. Regenxbio’s share price fell 32%
CalciMedica’s stock nosedived…
CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor in patients with acute kidney injury over a “safety concern.”
Boehringer Ingelheim has shared…
Boehringer Ingelheim has shared more phase 2 data on its kidney disease candidate apecotrep, shedding light on the decision to start a pivotal trial of the prospect last week.
Eli Lilly is continuing a run of…
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offerings by penning a pact with gene editing company Seamless Therapeutics.
Since launching one year ago with…
Since launching one year ago with a hearty $300 million series A, Kardigan has been on a biotech speedrun.
If the pursuit of Metsera signaled…
If the pursuit of Metsera signaled Novo Nordisk was ready to pay top dollar for the right innovation, the aftermath has filled Tamara Darsow’s calendar with high-stakes screenings for new opportunities.
The FDA is freeing Intellia’s…
The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister